Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Published:2021-10 Issue:10 Volume:22 Page:1378-1390
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Moreau Philippe,Hulin Cyrille,Perrot Aurore,Arnulf Bertrand,Belhadj Karim,Benboubker Lotfi,Béné Marie C,Zweegman Sonja,Caillon Hélène,Caillot Denis,Corre Jill,Delforge Michel,Dejoie Thomas,Doyen Chantal,Facon Thierry,Sonntag Cécile,Fontan Jean,Mohty Mohamad,Jie Kon-Siong,Karlin Lionel,Kuhnowski Frédérique,Lambert Jérôme,Leleu Xavier,Macro Margaret,Orsini-Piocelle Frédérique,Roussel Murielle,Stoppa Anne-Marie,van de Donk Niels W C J,Wuillème Soraya,Broijl Annemiek,Touzeau Cyrille,Tiab Mourad,Marolleau Jean-Pierre,Meuleman Nathalie,Vekemans Marie-Christiane,Westerman Matthijs,Klein Saskia K,Levin Mark-David,Offner Fritz,Escoffre-Barbe Martine,Eveillard Jean-Richard,Garidi Réda,Ahmadi Tahamtan,Krevvata Maria,Zhang Ke,de Boer Carla,Vara Sanjay,Kampfenkel Tobias,Vanquickelberghe Veronique,Vermeulen Jessica,Avet-Loiseau Hervé,Sonneveld Pieter

Funder

Janssen Research and Development LLC

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Emerging therapies for the treatment of relapsed or refractory multiple myeloma;Dimopoulos;Eur J Haematol,2011

2. Clinical course of patients with relapsed multiple myeloma;Kumar;Mayo Clin Proc,2004

3. Multiple myeloma: patient outcomes in real-world practice;Yong;Br J Haematol,2016

4. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma;Engelhardt;Haematologica,2014

5. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dimopoulos;Ann Oncol,2021

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Biological Therapies for Multiple Myeloma;Annual Review of Medicine;2024-01-29

2. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-01-25

3. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX;Blood Advances;2024-01-12

4. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial;Nature Medicine;2024-01-04

5. Management of Newly Diagnosed Multiple Myeloma Today, and in the Future;Hematology/Oncology Clinics of North America;2024-01